Table 1 Selected characteristics at presentation in 21 heart failure patients and healthy donors
Basic information | Heart failure patients n (percentage of 21) | Healthy donors | p value |
|---|---|---|---|
Age (years) | 34.6 ± 15.9 | 41.7 ± 4.0 | 0.07 |
Male (percentage) | 13 (61.9) | 9(100) | 0.07 |
NYHA functional class, n (percentage of 21) | |||
 II | 2 (9.5) |  |  |
 III | 7 (33.3) |  |  |
 IV | 12 (57.1) |  |  |
Comorbidities | |||
 Diabetes mellitus | 2 (9.5) |  |  |
 Smoking history | 5 (23.8) |  |  |
 Pulmonary hypertension | 5 (23.8) |  |  |
 Tricuspid regurgitation | 12 (57.1) |  |  |
 Mitral regurgitation | 17 (81.0) |  |  |
Ultrasonic cardiogram | |||
 LVEF (%) | 27.6 ± 9.8 |  |  |
 LA (mm) | 44.7 ± 4.8 |  |  |
 IVS-thickness (mm) | 8.2 ± 1.1 |  |  |
 LVEDD (mm) | 65.1 ± 16.6 |  |  |
Arrhythmia history, n (percentage of 21) | |||
 Atrial fibrillation | 4 (19.0) |  |  |
 Premature ventricular contraction | 6 (28.6) |  |  |
 Ventricular tachycardia | 4 (19.0) |  |  |
 Ventricular fibrillation | 1 (4.8) |  |  |
 CRBBB | 3 (14.3) |  |  |
Drug therapy, n (percentage of 21) | |||
 ASA | 2 (9.5) |  |  |
 Amio | 4 (19.0) |  |  |
 β-Blocker | 15 (71.4) |  |  |
 Digoxin | 16 (76.2) |  |  |
 ACEI/ARB | 17 (81.0) |  |  |
 CCB | 3 (14.3) |  |  |
 Diuretic | 18 (85.7) |  |  |